Hazlett, Burt & Watson’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6K Hold
100
﹤0.01% 757
2025
Q4
$7K Hold
100
﹤0.01% 748
2025
Q3
$7K Hold
100
﹤0.01% 699
2025
Q2
$9K Hold
100
﹤0.01% 599
2025
Q1
$7K Sell
100
-17
-15% -$1.39K ﹤0.01% 619
2024
Q4
$9K Sell
117
-10
-8% -$740 ﹤0.01% 556
2024
Q3
$9K Hold
127
﹤0.01% 542
2024
Q2
$14K Hold
127
0.01% 486
2024
Q1
$17K Hold
127
0.01% 455
2023
Q4
$15K Hold
127
0.01% 450
2023
Q3
$12K Buy
127
+10
+9% +$1.13K 0.01% 476
2023
Q2
$15K Buy
117
+17
+17% +$2.06K 0.01% 438
2023
Q1
$12K Hold
100
0.01% 430
2022
Q4
$11K Hold
100
0.01% 446
2022
Q3
$8K Hold
100
0.01% 472
2022
Q2
$7K Hold
100
0.01% 479
2022
Q1
$13K Buy
+100
New +$10.9K 0.01% 444

Other funds holding DXCM

Hazlett, Burt & Watson's DXCM Position: Q1 2026 in Review

Hazlett, Burt & Watson held its DexCom (DXCM) position steady in Q1 2026 at 100 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #757.

Hazlett, Burt & Watson first reported a position in DXCM in Q1 2022 and has held it in 17 quarters since. The position peaked at $17K in Q1 2024. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Hazlett, Burt & Watson held 100 shares of DexCom worth $6K as of Q1 2026.
  • Hazlett, Burt & Watson left its DexCom share count unchanged in Q1 2026.
  • DexCom made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #757 holding.
  • Hazlett, Burt & Watson first reported a position in DexCom in Q1 2022 and has held it in 17 quarters since.
  • Hazlett, Burt & Watson's DexCom position peaked at $17K in Q1 2024.
  • 957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.